HLS Therapeutics (OTCMKTS:HLTRF) Stock Falls 1.1% – Here’s What Happened

Shares of HLS Therapeutics Inc. (OTCMKTS:HLTRF) fell 1.1% during mid-day trading on Thursday. The stock traded as low as $2.79 and last traded at $2.79. Approximately 5,000 shares changed hands during mid-day trading, an increase of 254% from the average session volume of 1,413 shares. The stock had previously closed at $2.82.

Wall Street Analyst Weigh In

Separately, Raymond James Financial upgraded HLS Therapeutics from an “outperform” rating to a “strong-buy” rating in a report on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Strong Buy”.

HLS Therapeutics Stock Performance

The stock’s 50-day moving average is $2.83 and its 200-day moving average is $3.08.

About HLS Therapeutics

HLS Therapeutics Inc is a specialty pharmaceutical company focused on acquiring, developing and commercializing medicines in Canada and the United States. The company concentrates on products that address significant medical needs, with an emphasis on central nervous system and cardiovascular therapies.

HLS has commercialized branded prescription medicines and specialty products through partnerships, licensing arrangements and acquired product rights. Its portfolio has included Clozaril (clozapine), a treatment used in schizophrenia, as well as other therapies marketed through specialty-care and hospital channels.